GEPOTIDACIN AND VANCOMYCIN FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY STAPHYLOCOCCUS SAPROPHYTICUS
The present invention relates to methods for treating bacterial infections by Staphylococcus saprophyticus , which comprises administration of gepotidacin or pharmaceutically acceptable salts thereof, and vancomycin or a pharmaceutically acceptable salt thereof to a human in need thereof. Novel pharmaceutical combinations, compositions, resistance guided therapies and/or corresponding uses thereof are also disclosed.
1 . A method for treating an infection caused by Staphylococcus saprophyticus in a human in need thereof, comprising administering to said human a therapeutically effective amount of gepotidacin or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of vancomycin or a pharmaceutically acceptable salt thereof.
2 . A method as claimed in claim 1 , wherein the infection is a urinary tract infection.
3 . A method as claimed in claim 2 , wherein the infection is uncomplicated urinary tract infection.
4 . A method as claimed in claim 1 , wherein the gepotidacin or a pharmaceutically acceptable salt thereof, and vancomycin or a pharmaceutically acceptable salt thereof, are administered sequentially.
5 . A method as claimed in claim 1 , wherein the gepotidacin is gepotidacin methanesulphonate.
6 . A method as claimed in claim 1 , wherein the vancomycin is vancomycin hydrochloride.
7 . A method as claimed in claim 1 , wherein the gepotidacin or a pharmaceutically acceptable salt thereof is administered orally.
8 . A method as claimed in claim 1 , wherein the vancomycin or a pharmaceutically acceptable salt thereof is administered orally.
9 - 14 . (canceled)
15 . A pharmaceutical combination which comprises gepotidacin or a pharmaceutically acceptable salt thereof and vancomycin or a pharmaceutically acceptable salt thereof.
16 . A pharmaceutical composition which comprises gepotidacin or a pharmaceutically acceptable salt thereof, vancomycin or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient(s).
17 - 19 . (canceled)